<DOC>
	<DOC>NCT00956293</DOC>
	<brief_summary>This study wants to address whether a calcineurin-inhibitor (CNI)-free regimen six weeks after transplantation for Eurotransplant Senior Program (ESP) patients is as safe and well tolerated as standard treatment but optimizing immunosuppressive therapy with benefits in renal function, new-onset diabetes mellitus, cardiovascular risk, cancer and allograft nephropathy.</brief_summary>
	<brief_title>Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Inclusion criteria: Patients receiving a primary kidney from a donor aged &gt; 65 years In the Eurotransplant Senior Program Recipients of de novo cadaveric kidney transplants Exclusion criteria: Multiorgan recipients (e.g., kidney and pancreas) Patients receiving a kidney from a nonheart beating donor Patients who are recipients of ABO incompatible transplants Patients with already existing antibodies against the HLAtype of the receiving transplant Patients who have received an investigational immunosuppressive drug within four weeks prior to study entry (Baseline visit 1) Patients with thrombocytopenia, with an absolute neutrophil count of &lt; 1,500/mmÂ³ or leucopenia or hemoglobin &lt; 6 g/dL Patients who are HIV, HCV RNA, or Hepatitis B surface antigen positive Evidence of severe liver disease Females at randomization who will be not considered postmenopausal Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>